The FDA has accelerated approval of Genglycos, a gene therapy from Ultragenyx Pharmaceutical, for adults and children eight years and older with glycogen storage disease type Ia. According to Medscape, pariglasgene brecaparvovec-opnr is the first FDA-approved treatment for this condition. It is delivered as a single infusion through qualified treatment centers. The approval is for use alongside dietary management. The US wholesale price was reported at $2.7 million per patient, with availability expected within 30 to 60 days of the August 2026 announcement.
What the disease means for patients
GSDIa is a rare metabolic condition. A deficiency of the enzyme needed to release glucose from the liver into the bloodstream can trigger life-threatening hypoglycemia. The disorder affects between 1,500 and 2,500 patients in the US and 6,000 to 8,000 people worldwide. Until now, patients have been managed with raw corn starch supplementation, which can cause sharp blood sugar swings. GSDIa expert David Weinstein stated in an Ultragenyx press release that every missed corn starch dose carries risk of severe hypoglycemia, seizures and death.
The study backing approval
The approval rested on the randomized, double-blind phase 3 GlucoGene trial, in which 46 participants aged eight and older received Genglycos or placebo. Ultragenyx sponsored the GlucoGene study. The efficacy analysis included 44, the safety analysis 46 treated subjects. Compared to placebo, median daily corn starch intake fell by 31 percent. The number of daily corn starch doses also declined compared to baseline, a statistically significant difference. According to ClinicalTrials.gov, the study is complete; its results were first posted in the registry on October 14, 2026.
Side effects and their limits
Elevated liver enzymes, nausea, headache, constipation and elevated blood glucose were among the most common adverse effects. Hypertriglyceridemia occurred more often in gene therapy patients than placebo recipients: 29 percent versus 8 percent. Two clinical trials also documented anaphylaxis, adrenal insufficiency, elevated lactate and hypoglycemia as serious adverse events. FDA official Megha Kaushal said the accelerated approval reflects confidence in current clinical evidence, with further data to confirm long-term benefit.
Post-approval follow-up data required
As part of accelerated approval, Ultragenyx committed to providing two years of safety and efficacy data from open-label commercial treatment of 50 patients and 20 controls who could not receive Genglycos due to anti-AAV8 antibodies. Study participants are slated for disease monitoring at least ten years after infusion.